Back to Search
Start Over
Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model
- Source :
- PLoS Medicine. January 9, 2024, Vol. 21 Issue 1, e1004255
- Publication Year :
- 2024
-
Abstract
- Background Malaria transmission modelling has demonstrated the potential impact of semiquantitative glucose-6-phosphate dehydrogenase (G6PD) testing and treatment with single-dose tafenoquine for Plasmodium vivax radical cure but has not investigated the associated costs. This study evaluated the cost-effectiveness of P. vivax treatment with tafenoquine after G6PD testing using a transmission model. Methods and findings We explored the cost-effectiveness of using tafenoquine after G6PD screening as compared to usual practice (7-day low-dose primaquine (0.5 mg/kg/day) without G6PD screening) in Brazil using a 10-year time horizon with 5% discounting considering 4 scenarios: (1) tafenoquine for adults only assuming 66.7% primaquine treatment adherence; (2) tafenoquine for adults and children aged >2 years assuming 66.7% primaquine adherence; (3) tafenoquine for adults only assuming 90% primaquine adherence; and (4) tafenoquine for adults only assuming 30% primaquine adherence. The incremental cost-effectiveness ratios (ICERs) were estimated by dividing the incremental costs by the disability-adjusted life years (DALYs) averted. These were compared to a willingness to pay (WTP) threshold of US$7,800 for Brazil, and one-way and probabilistic sensitivity analyses were performed. All 4 scenarios were cost-effective in the base case analysis using this WTP threshold with ICERs ranging from US$154 to US$1,836. One-way sensitivity analyses showed that the results were most sensitive to severity and mortality due to vivax malaria, the lifetime and number of semiquantitative G6PD analysers needed, cost per malaria episode and per G6PD test strips, and life expectancy. All scenarios had a 100% likelihood of being cost-effective at the WTP threshold. The main limitations of this study are due to parameter uncertainty around our cost estimates for low transmission settings, the costs of G6PD screening, and the severity of vivax malaria Conclusions In our modelling study that incorporated impact on transmission, tafenoquine prescribed after a semiquantitative G6PD testing was highly likely to be cost-effective in Brazil. These results demonstrate the potential health and economic importance of ensuring safe and effective radical cure.<br />Author(s): David J. Price 1,2, Narimane Nekkab 3,4, Wuelton M. Monteiro 5,6, Daniel A. M. Villela 7, Julie A. Simpson 2, Marcus V. G. Lacerda 5,8, Michael T. White 9, [...]
- Subjects :
- Plasmodium vivax -- Identification and classification -- Control
Glucose-6-phosphate dehydrogenase deficiency -- Diagnosis -- Care and treatment
Primaquine -- Dosage and administration -- Comparative analysis
Malaria -- Risk factors -- Drug therapy -- Patient outcomes
Tafenoquine -- Dosage and administration -- Comparative analysis
Biological sciences
Subjects
Details
- Language :
- English
- ISSN :
- 15491277
- Volume :
- 21
- Issue :
- 1
- Database :
- Gale General OneFile
- Journal :
- PLoS Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.781962666
- Full Text :
- https://doi.org/10.1371/journal.pmed.1004255